Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19
TORONTO, June 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences […]